A response to infection in patients with severe sepsis - Do we need a "Stage-Directed Therapy Concept"?

Bratislava Medical Journal

Volumn 110, Issue 8, 2009, Pages 459-464

  Kula, R ^a   Chylek, V ^a   Szturz, P ^a   Sklienka, P ^a   Sukenik, P ^a   Tichy, J ^a   Maca, J ^a   Neiser, J ^a  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

Author keywords

Infection; Inflammatory response; Severe sepsis; Therapeutic intervention

Indexed keywords

ARTICLE; HUMAN; PATHOPHYSIOLOGY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

HUMANS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 68649098283     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS international sepsis definitions conference. Crit Care Med 2003; 31 (4): 1250-1256.
2. Vincent JL, Abraham E. The last 100 years of sepsis. Amer J Resp Crit Care Med 2006; 173 (3): 256-263.
3. Dos Santos CC, Slutsky AS. The contribution of biophysical lung injury to the development of biotrauma. Annu Rev Physiol 2006; 68: 585-618.
4. Medzhitov R, Janeway C Jr. Innate immunity. New Engl J Med 2000; 343 (5): 338-344.
5. Williams TJ. Oedema and vasodilatation in inflammation: the relevance of prostaglandins. Postgrad Med J 1977; 53 (625): 660-662.
6. Tees DF, Goetz DJ. Leukocyte adhesion: an exquisite balance of hydrodynamic and molecular forces. News Physiol Sci 2003; 18 (5): 186-190.
7. Van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001; 27 (6): 639-651.
8. Ali H, Haribabu B, Richardson RM, Snyderman R. Mechanisms of inflammation and leukocyte activation. Med Clin North Amer 1997; 81 (1): 1-28.
9. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Amer J Physiol Heart Circ Physiol 2005; 288 (3): H1016-H1021.
10. Tucker JJ, Wilson MA, Wead WB, Garrison RN. Microvascular endothelial cell control of peripheral vascular resistance during sepsis. Arch Surg 1998; 133 (12): 1335-1342.
11. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006; 12 (3): 151-170.
12. Hotchkiss RS, Swanson PE, Freeman BD et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27 (7): 1230-1251.
13. Brealey D, Karyampudi S, Jacques TS et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Amer J Physiol Regul Integr Comp Physiol 2004; 286 (3): R491-R497.
14. Singer M. Cellular dysfunction in sepsis. Clin Chest Med 2008; 29 (4): 655-660.
15. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve - an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52 (4): 595-638.
16. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New Engl J Med 1995; 332 (20): 1351-1362.
17. Hasday JD, Singh IS. Fever and the heat shock response: distinct, partially overlapping processes. Cell Stress Chaperones 2000; 5 (5): 471-480.
18. Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K. Leucocyte response and anti-inflammatory cytokines in community acquired pneumonia. Thorax 2001; 56 (2): 121-125.
19. Tracey KJ. The inflammatory reflex. Nature 2002; 420 (6917): 853-859.
20. Ulloa L. The vagus nerve and the nicotinic anti-inflammatory pathway. Nat Rev Drug Discov 2005; 4 (8): 673-684.
21. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Amer J Resp Crit Care Med 2001; 163 (2): 316-321.
22. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med 2005; 11 (2): 56-63.
23. Van Eijk LT, Pickkers P, Smits P, van den Broek W, Bouw MP, van der Hoeven JG. Microvascular permeability during experimental human endotoxemia: an open intervention study. Critical Care 2005; 9 (2): R157-R164.
24. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005; 9(Suppl4): S13-S19.
25. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. New Engl J Med 2003; 348 (2): 138-150.
26. Englert JA, Fink MP. The multiple organ dysfunction syndrome and late-phase mortality in sepsis. Curr Infect Dis Rep 2005; 7 (5): 335-341.
27. Munford RS, Tracey KJ. Is severe sepsis a neuroendocrine disease? Mol Med 2002; 8 (8): 437-442.
28. Allary J, Annane D. Glucocorticoids and sepsis. Minerva Anestesiol 2005; 71 (12): 759-768.
29. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7): 1303-1310.
30. Su F, Nguyen ND, Wang Z, Cai Y, Rogiers P, Vincent JL. Fever control in septic shock: beneficial or harmful? Shock 2005; 23 (6): 516-520.
31. Vincent JL, Bihari D, Suter PM et al. The prevalence of nosoco-mial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC Internati onal Advisory Committee. J Amer Med Ass 1995; 274 (8): 639-644.
32. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34 (6): 1589-1596.
33. Jaeschke RZ, Brozek JL, Dellinger RP. 2008 update of international guidelines for the management of severe sepsis and septic shock: should we change our current clinical practice? Pol Arch Med Wewn 2008; 118 (3): 92-95.
34. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 2001; 345 (19): 1368-1377.
35. Gattinoni L, Brazzi L, Pelosi P et al. A trial of goal-oriented hemo-dynamic therapy in critically ill patients. New Engl J Med 1995; 333 (16): 1025-1032.
36. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. New Engl J Med 1994; 330 (24): 1717-1722.
37. Protti A, Singer M. Strategies to modulate cellular energetic metabolism during sepsis. Novartis Found Symp 2007; 280: 7-16.
38. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New Engl J Med 2005; 353 (13): 1332-1341.
39. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhai-naut JF et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33 (10): 2266-2277.
40. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344 (10): 699-709.